169 related articles for article (PubMed ID: 31323633)
1. To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.
Paľa A; Coburger J; Scherer M; Ahmeti H; Roder C; Gessler F; Jungk C; Scheuerle A; Senft C; Tatagiba M; Synowitz M; Wirtz CR; Schmitz B; Unterberg AW
J Neurosurg; 2019 Jul; 133(2):273-280. PubMed ID: 31323633
[TBL] [Abstract][Full Text] [Related]
2. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
3. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Qiu X; Chen Y; Bao Z; Chen L; Jiang T
Radiother Oncol; 2022 Feb; 167():1-6. PubMed ID: 34902368
[TBL] [Abstract][Full Text] [Related]
5. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA
Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
7. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.
Youland RS; Kreofsky CR; Schomas DA; Brown PD; Buckner JC; Laack NN
J Neurooncol; 2017 Dec; 135(3):535-543. PubMed ID: 28836106
[TBL] [Abstract][Full Text] [Related]
8. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
9. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
Ziu M; Kalkanis SN; Gilbert M; Ryken TC; Olson JJ
J Neurooncol; 2015 Dec; 125(3):585-607. PubMed ID: 26530261
[TBL] [Abstract][Full Text] [Related]
10. Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.
Liu Y; Liu S; Li G; Li Y; Chen L; Feng J; Yang Y; Jiang T; Qiu X
Cancer; 2022 Mar; 128(5):1085-1092. PubMed ID: 34780673
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Nahed BV; Redjal N; Brat DJ; Chi AS; Oh K; Batchelor TT; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):609-30. PubMed ID: 26530264
[TBL] [Abstract][Full Text] [Related]
15. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
16. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
McTyre E; Lucas JT; Helis C; Farris M; Soike M; Mott R; Laxton AW; Tatter SB; Lesser GJ; Strowd RE; Lo HW; Debinski W; Chan MD
Am J Clin Oncol; 2018 Aug; 41(8):813-819. PubMed ID: 28301347
[TBL] [Abstract][Full Text] [Related]
17. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X
J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Different Postoperative Adjuvant Regimens in Patients with Low-Grade Gliomas: A Network Meta-Analysis.
Dongpo S; Xiaozhuo L; Xin L; Zhengyao Z; Qing W; Fameng Z; Mingming F; Qian H; Mei L; Tong C
World Neurosurg; 2023 Nov; 179():e474-e491. PubMed ID: 37673325
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
Minniti G; Paolini S; Antonelli M; Gianno F; Tini P; Lanzetta G; Arcella A; De Pietro R; Giraffa M; Capone L; Romano A; Bozzao A; Esposito V
J Neurooncol; 2023 Sep; 164(2):331-339. PubMed ID: 37665475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
